RSG, a PPARγ agonist typically used to treat T2DM patients (18,19), significantly reduces homocysteine-induced reactive oxygen species and the secretion of MCP-1 and IL-8 in human monocytes. This evidence concerns the gene PPARG and type 2 diabetes mellitus.